ReviewCritical reviews in oncology/hematology2020
Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective.
Review in Critical reviews in oncology/hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiotherapy based management during Covid-19 pandemic - A systematic review of presented consensus and guidelines.Critical reviews in oncology/hematology · 2021Pooled it
- [Current Status of Multidisciplinary Team Consultation for Lung Cancer and Prospects under the Empowerment of Medical Large Models].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Impact of the COVID-19 pandemic on lung cancer screening utilization and outcome: a health examination center retrospective study.Annals of medicine · 2025Article
- Article
- Diagnostic and therapeutic delays in lung cancer during the COVID-19 pandemic: a single center experience at a German Cancer center.BMC pulmonary medicine · 2024Article
- Article
- Lung Cancer Treatment Trends During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Claims and Order Data Analysis (2019-2021).JTO clinical and research reports · 2023Article
- CT Scan-Guided Fine Needle Aspiration Cytology for Lung Cancer Diagnosis through the COVID-19 Pandemic: What We Have Learned.Tomography (Ann Arbor, Mich.) · 2023Article
- Outcomes of Thoracoscopic Lobectomy after Recent COVID-19 Infection.Pathogens (Basel, Switzerland) · 2023Article
- Impact of coronavirus disease 2019 on lung cancer patients: A meta-analysis.Translational oncology · 2023Article
- COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges.The Journal of international medical research · 2022Review
- Major Pulmonary Resection for Non-Small Cell Lung Carcinoma during the COVID-19 Pandemic-Single Israeli Center Cross-Sectional Study.Journal of clinical medicine · 2022Article
- Severity of COVID-19 in patients with lung cancer: evidence and challenges.Journal for immunotherapy of cancer · 2021Review
- A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic.Mediastinum (Hong Kong, China) · 2021Review
- Perspective: Did Covid-19 Change Non-small Cell Lung Cancer Surgery Approach?Frontiers in surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of patients with lung cancer during the current COVID-19 pandemic is challenging. Lung cancer is a heterogenous disease with a wide variety of therapeutic options. Oncologists have to determine the risks and benefits of modifying the treatment plans of patients especially in situation where the disease biology and treatment are complex. Health care visits carry a risk of transmission of SARS-CoV-2 and the similarities of COVID-19 symptoms and lung cancer manifestations represent a dominant problem. Efforts to modify treatment of lung cancer during the current pandemic have been adapted by many healthcare institutes to reduce exposure of lung cancer patients to SARS-CoV-2. We summarized the implications of COVID-19 pandemic on the management of lung cancer from the perspective of different specialties of thoracic oncology multidisciplinary team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.